Physiology. COX-2 inhibitors and cardiovascular risk.
Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. cpcannon@partners.org
Christopher P
CP
Cannon
Paul J
PJ
Cannon
D000818:Animals; D002318:Cardiovascular Diseases / Q000139:chemically induced; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D042783:Endothelial Cells / Q000201:enzymology*; D011464:Epoprostenol / Q000378:metabolism; D005818:Genetic Engineering; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000201:enzymology*; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced*
D052246:Cyclooxygenase 2 Inhibitors; D011464:Epoprostenol; D051546:Cyclooxygenase 2